 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- 90Y-NM600 / Archeus Technologies
Radionuclide-specific effects of90Y-,177Lu-, or225Ac-NM600 targeted radionuclide therapy on tumor immunomodulation and enhanced immunotherapy response in syngeneic murine tumors (Section 24; Poster Board #20) - Mar 14, 2023 - Abstract #AACR2023AACR_8505;
or ?, affect the timing, magnitude, and molecular pathways leading to this IFN1 response. Understanding TRT effects on the tumor microenvironment may optimize TRT and immunotherapy.
- 90Y-NM600 / Archeus Technologies
Radionuclide-specific effects of 90Y-, 177Lu-, or 225Ac-NM600 targeted radionuclide therapy on tumor immunomodulation and enhancing immunotherapy response in murine tumor models (Section 35) - Mar 9, 2022 - Abstract #AACR2022AACR_3435;
The physical properties of the delivered radionuclide dictate timing and magnitude of the IFN1 response stimulated by TRT. Understanding these effects may be critical to safely and effectively integrating TRT and immunotherapies to enhance anti-tumor immunity in cancer patients.
- || 90Y-NM600 / Archeus Technologies, lorukafusp alfa (APN301) / Apeiron Biologics
Clinical, Journal: Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting. (Pubmed Central) - Dec 16, 2021
The combination of external beam radiotherapy, intratumoral immunocytokine, and targeted radionuclide immuno-radiotherapy known to have activity against syngeneic melanoma in murine models is feasible and well tolerated in companion dogs with advanced stage, spontaneously arising melanoma or osteosarcoma and has immunomodulatory potential. Further studies evaluating the dose-dependent immunomodulatory effects of this immuno-radiotherapy combination are currently ongoing.
- 90Y-NM600 / Archeus Technologies, Provenge (sipuleucel-T) / Bausch Health
Combination of antigen-specific vaccination and targeted radionuclide therapy improves anti-tumor efficacy in a murine prostate model (Poster Hall) - Oct 1, 2021 - Abstract #SITC2021SITC_1032;
Background While checkpoint blockade has been unsuccessful in prostate cancer trials, the approval of Sipuleucel-T demonstrates the value of antigen-specific vaccination approaches for this disease...An intravenous injection was administered of 50 (”low-dose”) or 250 μCi (”high dose”) of 90Y-NM600, estimated to deliver a dose of 3.1 Gy or 15.5 Gy to 300 mm3 tumors, respectively...Conclusions These data suggest that the combination of antigen-specific vaccination and TRT can be an effective treatment for cancers that are refractory to immunotherapy. This combination may act through increasing co-stimulation by dendritic cells, leading to a more active cytolytic CD8+ T cell population.
- bempegaldesleukin (NKTR-214) / Nektar Therap, BMS, Ono Pharma, 90Y-NM600 / Archeus Technologies
[VIRTUAL] Mechanisms of cooperative response to bempegaldesleukin (BEMPEG) and 90Y-NM600 targeted radionuclide therapy in the treatment of a syngeneic murine model of head and neck squamous cell carcinoma () - Mar 13, 2021 - Abstract #AACR2021AACR_4723;
These results suggest a synergistic interaction between BEMPEG and 90Y-NM600 that improves the immune microenvironment in this difficult to treat murine model of HNSCC, which may thereby enhance the response to immune checkpoint blockade. Further studies are warranted to examine the therapeutic implications of this combination in patients.
- 90Y-NM600 / Archeus Technologies
[VIRTUAL] Temporal analysis of type 1 interferon activation in tumor cells following external beam radiotherapy or targeted radionuclide therapy () - Mar 13, 2021 - Abstract #AACR2021AACR_4400;
We show the potential of TRT to stimulate IFN1 activation that is comparable to that observed with EBRT of equivalent cumulative dose. Further evaluation of the timing and magnitude of IFN1 response following EBRT and TRT may be critical to the optimal integration with immunotherapies.
- bempegaldesleukin (NKTR-214) / Nektar Therap, BMS, Ono Pharma, 90Y-NM600 / Archeus Technologies
[VIRTUAL] In vivo synergy of 90Y-NM600 and Bempegaldesleukin improves anti-tumor efficacy of immune checkpoint inhibitors in syngeneic murine cancer models () - Mar 11, 2021 - Abstract #AACR2021AACR_940;
Combination of 90Y-NM600, BEMPEG, and ICI displays robust anti-tumor activity that prevents metastatic disease progression and prolongs survival in spontaneously metastatic, immunologically “cold” tumor models. Clinical studies are warranted to test the safety and efficacy of this promising combined modality treatment regimen.